Art. -Nr.: HY-100714

DL-AP5

(Synonyms: 2-APV; DL-2-Amino-5-phosphonovaleric acid)

3 Cited Publications

Kundenbewertung

Based on 3 publication(s) in Google Scholar

DL-AP5 (2-APV) is a competitive NMDA (N-methyl-D-aspartate) receptor antagonist. DL-AP5 shows significantly antinociceptive activity. DL-AP5 specifically blocks on channels in the rabbit retina.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.70%
CAS. Nr.: 76326-31-3
Formel: C₅H₁₂NO₅P
Molecular Weight:197.13

Speicherung:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

DL-AP5 Chemical Structure

CAS. Nr.: 76326-31-3

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Other Forms of DL-AP5:

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (3)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

DL-AP5 (2-APV) is a competitive NMDA (N-methyl-D-aspartate) receptor antagonist. DL-AP5 shows significantly antinociceptive activity. DL-AP5 specifically blocks on channels in the rabbit retina^[1]^[2]^[3].

IC₅₀ & Target

NMDA Receptor

Alle iGluR Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
Pyramidal neuron	IC₅₀	0.31 μM Compound: L-AP5	sensitization of CA1 pyramidal neurons by 2 to depolarizations by L-AP4,L-AP5 and L-AP6 after exposure to quisqualic acid sensitization of CA1 pyramidal neurons by 2 to depolarizations by L-AP4,L-AP5 and L-AP6 after exposure to quisqualic acid	[PMID: 7966155]
Pyramidal neuron	IC₅₀	2.2 μM Compound: L-AP5	sensitization of CA1 pyramidal neurons by 2 to depolarizations by L-AP4, L-AP5 and L-AP6 after reversal with L-alpha-AA sensitization of CA1 pyramidal neurons by 2 to depolarizations by L-AP4, L-AP5 and L-AP6 after reversal with L-alpha-AA	[PMID: 7966155]
Pyramidal neuron	IC₅₀	2.3 μM Compound: L-AP5	sensitization of CA1 pyramidal neurons by 2 to depolarizations by L-AP4, L-AP5 and L-AP6 before exposure to quisqualic acid sensitization of CA1 pyramidal neurons by 2 to depolarizations by L-AP4, L-AP5 and L-AP6 before exposure to quisqualic acid	[PMID: 7966155]

In Vitro

DL-AP5 (100 μM) partially prevents glutamate-induced increase in Arc/Arg3.1 protein levels^[5].
DL-AP5 decreases the NMDA-induced Arc/Arg3.1 upregulation^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

DL-AP5 (0-10 μg/rat, Intra-CA1) significantly decreases the effect of NMDA^[3].
DL-AP5 (0-10 nmol, Intracerebroventricular injection) causes a dose-dependent increase in food consumption^[4].
DL-AP5 (5 nmol, Intracerebroventricular injection) attenuates the decreased food consumption induced by the intracerebroventricular injection of ghrelin^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male Wistar rats (180-230 g)^[3]
Dosage:

1, 3.2 and 10 μg/rat
Administration:

Injected into the intra-dorsal hippocampal (intra-CA1) immediately after shock administration, once
Result:

Significantly decreased the effect of NMDA (10^-2 μg/rat, intra-CA1) with significant interaction.

Animal Model:

Broilers cockerels (3-h fooddeprived (FD3), n=8 for each group)^[4]
Dosage:

0, 2.5, 5, and 10 nmol; in a volume of 10 μL
Administration:

Intracerebroventricular injection
Result:

Caused a dose-dependent increase in food consumption which was significant for 5 and 10 nmol doses.

Animal Model:

Broilers cockerels (3-h fooddeprived (FD3), n=8 for each group)^[4]
Dosage:

5 nmol
Administration:

Intracerebroventricular injection, followed by ghrelin (0.6 nmol)
Result:

Attenuated the decreased food consumption induced by the intracerebroventricular injection of ghrelin.

Chemical Information

CAS. Nr. 76326-31-3
Appearance Solid
Molecular Weight 197.13
Formel C₅H₁₂NO₅P
Color White to off-white
SMILES

NC(CCCP(O)(O)=O)C(O)=O
Synonyms

2-APV; DL-2-Amino-5-phosphonovaleric acid
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (3)

All In Vivo Efficacy StudyBio/Physico-chemical Assay

Sort by:

Journal Impact Factor

Neuron

Dual anterior insula-prefrontal cortex circuits mediate chronic stress-induced social interaction deficits. [Abstract]

2026 Mar 26:S0896-6273(26)00120-0. PMID: 41895265
Int J Biol Macromol

SETD2 deficiency in peripheral sensory neurons induces allodynia by promoting NMDA receptor expression through NFAT5 in rodent models. [Abstract]

2024 Dec;282(Pt 5):136767. PMID: 39476923

DL-AP5 purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2024 Dec;282(Pt 5):136767. [Abstract]

Effects of a single injection of DL-AP5 (5 μg; i.t.) on the tactile and pressure withdrawal thresholds and heat withdrawal latency within 2 h in KD-Setd2 and NC rats.

DL-AP5 purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2024 Dec;282(Pt 5):136767. [Abstract]

The mean changes of baseline values and the DL-AP5 (50 μM) effect on the frequency and amplitude of mEPSCs in spinal dorsal horn neurons of Setd2^fl/fl and Setd2-cKO mice.
bioRxiv

2025 July 07.

DL-AP5 purchased from MedChemExpress. Usage Cited in: bioRxiv. 2025 July 07.

DL-AP5 (50 μM) abolished the training effect so that trained and untrained trajectories overlapped in the CNS-3D organoids.

DL-AP5 purchased from MedChemExpress. Usage Cited in: bioRxiv. 2025 July 07.

DL-AP5 (50 μM) suppressed activity-dependent neuronal recruitment and blocked stimulation-driven LTP in CNS-3D organoid networks, as the number of unique neurons remained low under NMDA receptor blockade.

DL-AP5 purchased from MedChemExpress. Usage Cited in: bioRxiv. 2025 July 07.

DL-AP5 (200 μM). Heat map of GSVA scores across 15 GO terms associated with learning, memory, LTP, and synaptic plasticity.

Lösungsmittel & Löslichkeit

In Vitro:

H₂O : 33.33 mg/mL (169.08 mM; ultrasonic and warming and heat to 60°C)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

5.0728 mL

25.3640 mL

50.7279 mL

5 mM

1.0146 mL

5.0728 mL

10.1456 mL

10 mM

0.5073 mL

2.5364 mL

5.0728 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 50 mg/mL (253.64 mM); Clear solution; Need ultrasonic

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Murray CW, et al. Neurokinin and NMDA antagonists (but not a kainic acid antagonist) are antinociceptive in the mouse formalin model. Pain. 1991;44(2):179-185. [Content Brief]

[2]. Massey SC, et al. N-methyl-D-aspartate receptors of ganglion cells in rabbit retina. J Neurophysiol. 1990;63(1):16-30. [Content Brief]

[3]. Jafari-Sabet M. NMDA receptor blockers prevents the facilitatory effects of post-training intra-dorsal hippocampal NMDA and physostigmine on memory retention of passive avoidance learning in rats. Behav Brain Res. 2006 Apr 25;169(1):120-7. [Content Brief]

[4]. Taati M, et al. The effects of DL-AP5 and glutamate on ghrelin-induced feeding behavior in 3-h food-deprived broiler cockerels. J Physiol Biochem. 2011 Jun;67(2):217-23. [Content Brief]

[5]. Chen T, et al. Glutamate-induced rapid induction of Arc/Arg3.1 requires NMDA receptor-mediated phosphorylation of ERK and CREB. Neurosci Lett. 2017 Nov 20;661:23-28. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O	1 mM	5.0728 mL	25.3640 mL	50.7279 mL	126.8199 mL
	5 mM	1.0146 mL	5.0728 mL	10.1456 mL	25.3640 mL
	10 mM	0.5073 mL	2.5364 mL	5.0728 mL	12.6820 mL
	15 mM	0.3382 mL	1.6909 mL	3.3819 mL	8.4547 mL
	20 mM	0.2536 mL	1.2682 mL	2.5364 mL	6.3410 mL
	25 mM	0.2029 mL	1.0146 mL	2.0291 mL	5.0728 mL
	30 mM	0.1691 mL	0.8455 mL	1.6909 mL	4.2273 mL
	40 mM	0.1268 mL	0.6341 mL	1.2682 mL	3.1705 mL
	50 mM	0.1015 mL	0.5073 mL	1.0146 mL	2.5364 mL
	60 mM	0.0845 mL	0.4227 mL	0.8455 mL	2.1137 mL
	80 mM	0.0634 mL	0.3170 mL	0.6341 mL	1.5852 mL
	100 mM	0.0507 mL	0.2536 mL	0.5073 mL	1.2682 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

DL-AP5

3 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

DL-AP5

Immunology/Inflammation Compound Library

Membrane Transporter/Ion Channel Compound Library

Neuronal Signaling Compound Library

Neurotransmitter Receptor Compound Library

Anti-Alzheimer's Disease Compound Library

Neuroprotective Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Antidepressant Compound Library

Human Metabolite Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Ion Channel Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) DL-AP5

Alle iGluR Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (3)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

DL-AP5

Immunology/Inflammation Compound Library

Membrane Transporter/Ion Channel Compound Library

Neuronal Signaling Compound Library

Neurotransmitter Receptor Compound Library

Anti-Alzheimer's Disease Compound Library

Neuroprotective Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Antidepressant Compound Library

Human Metabolite Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Ion Channel Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) DL-AP5

Alle iGluR Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (3)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

DL-AP5 Related Classifications

HY-100714 Related Classifications